已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Changes to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995–2018)

医学 肌萎缩侧索硬化 利鲁唑 比例危险模型 危险系数 纪元(天文学) 生存分析 队列 人口 儿科 多元分析 内科学 置信区间 疾病 星星 物理 环境卫生 天文
作者
Rosario Vasta,Filippo De Mattei,Salvatore Tafaro,Antonio Canosa,Umberto Manera,Maurizio Grassano,Francesca Palumbo,Sara Cabras,Enrico Matteoni,Francesca Di Pede,Grazia Zocco,Giorgio Pellegrino,Emilio Minerva,Daniela Pascariu,Barbara Iazzolino,Stefano Callegaro,Giuseppe Fuda,Paolina Salamone,Fabiola De Marchi,Letizia Mazzini
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:104 (8) 被引量:1
标识
DOI:10.1212/wnl.0000000000213467
摘要

The average survival of patients with amyotrophic lateral sclerosis (ALS) ranges from 2 to 5 years from symptom onset. However, it remains unclear whether this estimate has improved over time. The objective of this study was to analyze the survival trend of a large population-based cohort of patients with ALS over a 24-year period. Patients from the Piemonte and Valle d'Aosta registry for ALS (PARALS) were categorized into the first (1995-2002), second (2003-2010), or third (2011-2018) epoch based on their diagnosis date. Survival was defined as the time from diagnosis to death, tracheostomy, or censoring date. A Cox proportional hazard model was developed with diagnosis epoch as the primary variable of interest, adjusted for sex, site of onset, age at onset, diagnostic delay, forced vital capacity at diagnosis, Δbody mass index from onset to diagnosis, noninvasive mechanical ventilation use, gastrostomy use, and site of follow-up. A subset analysis comparing the 2007-2012 and 2013-2018 cohorts was conducted, incorporating riluzole prescription, genetics, and preslope category as additional covariates. A total of 3,134 patients were included, evenly distributed across the 3 epochs (990, 1,023, and 1,121, respectively). The median survival remained stable during the first and second epoch (18.6 months vs 18.3 months) but improved during the third epoch (20.1 months; p = 0.0041), with a hazard ratio (HR) of 0.76 (95% CI 0.67-0.87, p = 0.00003). In the subset analysis, the most recent epoch (2013-2018) showed a continued survival advantage (HR 0.77, 95% CI 0.65-0.90). Of interest, the survival benefit was only evident among intermediate progressors (HR 0.60, 95% CI 0.45-0.80). In the PARALS, ALS survival increased over time. In a subset analysis, the beneficial effect of the epoch was only evident among intermediate progressors. The improvement in multidisciplinary care provided by tertiary centers may be one possible explanation for this finding, although further dedicated studies are needed to confirm this hypothesis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威武的若山完成签到,获得积分10
3秒前
清爽老九的应助被元骏采纳,获得20
3秒前
影2857完成签到,获得积分10
3秒前
Ico发布了新的文献求助18
8秒前
典雅夏之发布了新的文献求助10
8秒前
Ali发布了新的文献求助10
9秒前
雪儿完成签到,获得积分10
10秒前
诚心文博完成签到,获得积分10
12秒前
崔洪瑞完成签到,获得积分10
12秒前
19秒前
勤奋的白萱完成签到,获得积分10
19秒前
所所的应助被典雅夏之采纳,获得10
21秒前
23秒前
liuliu发布了新的文献求助10
25秒前
Ava的应助被江清月近人采纳,获得10
26秒前
太阳发布了新的文献求助30
27秒前
ixA完成签到,获得积分10
30秒前
mk91完成签到,获得积分10
31秒前
34秒前
sdjf完成签到,获得积分10
35秒前
秋子david完成签到,获得积分10
36秒前
suye完成签到,获得积分10
37秒前
41秒前
初夏发布了新的文献求助10
42秒前
美叽完成签到 ,获得积分10
43秒前
七叶花开完成签到,获得积分10
44秒前
秋秋完成签到,获得积分10
44秒前
英俊的铭的应助被科研通管家采纳,获得10
45秒前
慕青的应助被科研通管家采纳,获得10
45秒前
clamdown的应助被科研通管家采纳,获得10
45秒前
英姑的应助被科研通管家采纳,获得10
45秒前
Moooi完成签到,获得积分10
47秒前
超级冷梅完成签到,获得积分10
47秒前
Lucky完成签到 ,获得积分10
47秒前
50秒前
cc完成签到 ,获得积分10
52秒前
可爱的函函的应助被玛卡巴卡采纳,获得10
52秒前
失眠的以松完成签到,获得积分10
52秒前
谦让的代桃完成签到 ,获得积分10
53秒前
why发布了新的文献求助10
54秒前
高分求助中
(应助此贴封号)通过应助OA文献获取积分 10000
Rosenblum, Global Change Biology 800
The Dawn of Philology 520
Organizational Behavior 510
Management and the Arts 510
Production Logging: Theoretical and Interpretive Elements 400
A primer on partial least squares structural equation modeling (PLS-SEM) (4th ed.) 310
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 内科学 物理 有机化学 化学工程 生物化学 复合材料 光电子学 细胞生物学 心理学 量子力学 催化作用 物理化学 电极
热门帖子
关注 科研通微信公众号,转发送积分 7820028
求助须知:如何正确求助?哪些是违规求助? 9347684
关于积分的说明 20542516
捐赠科研通 7412613
什么是DOI,文献DOI怎么找? 3332529
关于科研通互助平台的介绍 2478486
邀请新用户注册赠送积分活动 2352506